Key Metrics
11.75
Heat Index-
Impact LevelMedium
-
Scope LevelGlobal
-
Last Update2026-03-03
Key Impacts
Positive Impacts (3)
Arbutus Biopharma Corp. (ABUS)
Specialty Lipid Nanoparticle (LNP) Material Suppliers
Patent-Litigation Finance Firms
Negative Impacts (3)
Moderna Inc. (MRNA)
mRNA Therapeutics Developers
U.S. Biotechnology ETF (XBI)
Total impacts: 8 |
Positive: 3 |
Negative: 3
Event Overview
The settlement highlights the significant financial stakes in pharmaceutical intellectual property disputes, reflecting the value of proprietary technology in the biotech industry. The agreement includes a substantial upfront payment and potential additional payments contingent on legal outcomes.
Collect Records
Moderna Settles Global Patent Litigation with Arbutus and Genevant
2026-03-04 05:45
Moderna has reached a global patent litigation settlement with Arbutus and Genevant. As part of the agreement, Moderna will pay an initial $950 million in July 2026. Additionally, there is a potential for an extra payment of up to $1.3 billion based on the outcome of an appeal, bringing the total potential payment to up to $2.25 billion.
Total records: 1